MYGNMyriad Genetics, Inc.
$4.18-45% 1Y
$4.18
$2.8752 weeks$8.18
The financials
Myriad Genetics, Inc. by the numbers
Myriad Genetics, Inc. (MYGN) reported revenue of $191M in Q2 2027 (quarter ended Jun 30, 2026), down 11% from the same quarter a year earlier. That came with a gross margin of 67% and net loss of $43M. For the full year FY2026, revenue was $825M (−1.6% year on year) and net income −$366M. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
| Income statement | Q2 2027 | Q2 2026 | Change |
|---|---|---|---|
| Revenue | $191M | $213M | −11% |
| Gross profit | $127M | $152M | −16% |
| Operating income | −$39M | −$329M | n/a |
| Net income | −$43M | −$331M | n/a |
| Diluted EPS | −$0.46 | −$3.57 | n/a |
Diagnostics & Research
Ranks #17 of 21 by RyuScore